Drug Profile
SAR 103168
Alternative Names: SAR103168Latest Information Update: 29 Feb 2012
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Developer Sanofi
- Class Antineoplastics; Small molecules
- Mechanism of Action Protein kinase inhibitors; STAT5 transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Acute myeloid leukaemia
Most Recent Events
- 08 Feb 2012 Discontinued - Phase-I for Acute myeloid leukaemia in USA (IV)
- 25 Sep 2009 Phase-I clinical trials in Acute myeloid leukaemia in USA (IV)